Business Context and Reporting Period
Quince Therapeutics, Inc. (QNCX) filed a Form 8-K on August 31, 2026, reporting a material event regarding its continued listing status on the Nasdaq Global Select Market. The filing addresses a deficiency in stockholders' equity identified in the Company's Form 10-Q for the quarter ended June 30, 2026.
Key Financial Metrics
- Stockholders' Equity: ($35,324,000) as of June 30, 2026.
- Minimum Equity Requirement: $10,000,000 per Nasdaq Listing Rule 5450(b)(1)(A).
- Revenue, Profit, Cash Flow, Debt: The filing text does not provide specific values for revenue, profit, cash flow, margins, or debt levels.
Material Changes and Listing Status
The Company received a written notification from Nasdaq on August 31, 2026, stating it failed to meet the minimum stockholders' equity requirement. While the common stock continues to trade under the symbol "QNCX" with no immediate effect on listing, the Company is in non-compliance.
- Compliance Deadline: The Company has 45 calendar days (until October 15, 2026) to submit a plan to regain compliance.
- Extension Possibility: If a plan is accepted, Nasdaq may grant up to 180 calendar days (until February 27, 2027) to evidence compliance.
- Appeal Rights: If the plan is not accepted, the Company retains the right to appeal, during which the stock remains listed.
Outlook, Management Commentary, and Risks
Management is evaluating alternative courses of action to regain compliance. The Company previously filed an Initial Listing Application with Nasdaq and disclosed in a proxy statement (filed August 25, 2026) a potential name change to "IRulya Therapeutics Inc." and a transfer of trading to the Nasdaq Capital Market under the symbol "IRLA," contingent upon shareholder approval.
Risks and Contingencies:
- There is no assurance the Company will regain compliance with the minimum equity requirement.
- There is no assurance that the Initial Listing Application or Required Company Stockholder Matters will be approved.
- Failure to regain compliance or obtain approvals could result in delisting.
Investor Verification Checklist
- Verify the Company's plan to regain compliance submitted by October 15, 2026.
- Monitor the status of the Initial Listing Application and the proposed name change to "IRulya Therapeutics Inc."
- Review the definitive proxy statement (DEF14A) filed on August 25, 2026, for details on Required Company Stockholder Matters.
- Confirm whether the Company secures additional capital to address the ($35.3 million) negative equity position.